BiotechTube
Home/Pipeline/aPROMISE / PSMA-AI Enhancement

aPROMISE / PSMA-AI Enhancement

Prostate Cancer

CommercialActive

Key Facts

Indication
Prostate Cancer
Phase
Commercial
Status
Active
Company
EXINI Diagnostics

About EXINI Diagnostics

EXINI Diagnostics is a pioneer in AI-powered medical image analysis, with a 25-year history originating from Lund University research. Its core technology provides quantitative, reproducible assessments of bone, cardiac, brain, and PSMA PET scans, with its flagship automated Bone Scan Index (aBSI) platform deployed at approximately 1,000 hospitals worldwide. Acquired by Progenics Pharmaceuticals in 2015 and subsequently by Lantheus Holdings in 2020, EXINI now operates as a key AI and software arm within a larger, integrated diagnostics and therapeutics company. Its products are commercial-stage, revenue-generating tools used to support precision oncology and other diagnostic workflows.

View full company profile

Therapeutic Areas

OncologyCardiologyNeurology

Other Prostate Cancer Drugs

DrugCompanyPhase
APVO442Aptevo TherapeuticsPreclinical
APVO452Aptevo TherapeuticsDiscovery
BIO 300Humanetics Corp.Not Specified
OpaganibRedHill BiopharmaPhase 2
MagSense™ PSMA Imaging AgentImagion BiosystemsPre‑clinical
Small-Molecule TherapeuticAIkido LabsPre-clinical
LeronlimabCytoDynPreclinical
CROES RegistryAngioDynamicsPost-Market Registry
Cannabics® PRST-33CNBX PharmaceuticalsDiscovery
HDP-103Heidelberg PharmaPreclinical
ENV105Kairos PharmaPhase 2
AI for Prostate CancerInvenio ImagingResearch